SHR-9839

DRUG4 trials

Sponsors

Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Conditions

Advanced KRAS G12D Mutant Solid TumorsAdvanced Solid TumorAdvanced Solid TumorsNon-small Cell Lung Cancer (NSCLC)

Phase 1

The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors

RecruitingNCT05836948

Shanghai Hengrui Pharmaceutical Co., Ltd.Advanced Solid Tumor

Start: 2023-05-18End: 2026-06-01Target: 174Updated: 2025-08-11

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Active, not recruitingNCT06385678

Jiangsu HengRui Medicine Co., Ltd.Advanced KRAS G12D Mutant Solid Tumors

Start: 2024-07-05End: 2026-08-31Updated: 2025-09-19

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

RecruitingNCT06703177

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Advanced Solid Tumors

Start: 2025-02-18End: 2027-07-01Target: 876Updated: 2025-12-03

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC

RecruitingNCT06754930

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Non-small Cell Lung Cancer (NSCLC)

Start: 2025-02-18End: 2027-12-31Target: 400Updated: 2025-04-17